Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure

The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor‐positive early breast cancer after 2–3 years of tamoxifen. Patients with chemotherapy‐induced ovarian function failure (CIOFF) were also eligible, but could be at risk of ovarian function...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hellemond, Irene E.G., Vriens, Ingeborg J.H., Peer, Petronella G.M., Swinkels, Astrid C.P., Smorenburg, Carolien H., Seynaeve, Caroline M., van der Sangen, Maurice J.C., Kroep, Judith R., de Graaf, Hiltje, Honkoop, Aafke H., Erdkamp, Frans L.G., van den Berkmortel, Franchette W.P.J., de Boer, Maaike, de Roos, Wilfred K., Linn, Sabine C., Imholz, Alexander L.T., Tjan‐Heijnen, Vivianne C.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590217/
https://www.ncbi.nlm.nih.gov/pubmed/30588619
http://dx.doi.org/10.1002/ijc.32093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590217/
https://www.ncbi.nlm.nih.gov/pubmed/30588619
http://dx.doi.org/10.1002/ijc.32093

Ejemplares similares